Clinical Stage CAR-T for AL Amyloidosis and Select Immune-Mediated Diseases

February 2025

IMMiX BIOPHARMA

Disclaimer: Forward Looking Statements & Market Data

This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding Immix Biopharma, Inc.'s (the "Company") strategy, future operations, future financial position, projected costs, prospects, plans, and objectives of management, are forward-looking statements. The words ''anticipate,'' ''believe,'' ''continue,'' ''could,'' "depends," ''estimate,'' ''expect,'' ''intend,'' ''may,'' "ongoing," ''plan,'' ''potential,'' ''predict,'' ''project,'' ''target,'' ''should,'' "will," ''would,'' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements. In addition, the forward-looking statements included in this presentation represent the Company's views as of the date of this presentation.

The Company anticipates that subsequent events and developments will cause its views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this presentation. This presentation also includes data from other approved therapies and in trials, which are generated from separate, independent studies and do not come from head-to-head analysis. Differences exist between study or trial designs and subject characteristics, and caution should be exercised when comparing data across studies sourced from publicly available sources. This presentation also contains estimates and other statistical data made by independent parties and by us relating to market size and growth and data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions, and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk. These and other factors could cause results to differ materially from those expressed in the estimates made by the independent parties and by us.

Immix Biopharma Highlights

NXC-201: The only CAR-T in development for AL amyloidosis

- NXC-201 could transform the treatment of Relapsed/Refractory AL amyloidosis where no drugs are FDA approved today (~33,000 existing US patients, $3bn market);
- Ex-US study: 75% (12/16) Complete response (CR) rate in Relapsed/Refractory AL Amyloidosis
- US study: potentially pivotal; initial data in four patients consistent with Ex-US results (announced Dec 2024)
- Current standard-of-care CR rates as low as 3-20% in Relapsed/Refractory AL Amyloidosis

Sterically-optimized, proprietary CAR-T construct

- N-GENIUS platform produced NXC-201, our lead, sterically-optimized CAR-T
- NXC-201 CART construct provides barrier to entry: 3 key CAR modifications drive unique clinical profile - CD3ζγ, CD8 hinge, COBRA binder
- NXC-201 engineered specifically to solve for CAR-T tolerability (cytokine release syndrome, neurotoxicity)

Clinical profile ideal for select immune-mediated diseases

- Established clinical profile across large 129 patient dataset dosed with NXC-201: well-suited to treat select immune-mediated diseases
- In low volume diseases: no neurotoxicity; ~1-2 day cytokine release syndrome (CRS) duration

Source:. E Lebel et al. Efficacy and Safety of Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) for the Treatment of Relapsed and Refractory AL Amyloidosis. Presentation. ASH 2024. M. Assayag, et al. Asherie N, et al. Development and manufacture of novel locally produced anti-BCMA CAR T cells for the treatment of relapsed/refractory multiple myeloma: results from a phase I clinical trial. Haematologica. 2023 Jul 1;108(7):1827-1839. doi: 10.3324/haematol.2022.281628. PMID: 36200421; PMCID: PMC10316256. Quock TP, et al. Epidemiology of AL amyloidosis: a real-world study using US claims data. Blood Adv. 2018 May 22;2(10):1046-1053. doi: 10.1182/bloodadvances.2018016402. PMID: 29748430. Staron A, et al. Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history study. Blood Cancer J. 2021;11(8):139. PMID: 34349108 PMCID: PMC8338947 DOI: 10.1038/s41408-021-00529-w. 129 patients treated composed: a) ex-US: 96 Multiple Myeloma patients at high dose presented at ASH 2024, 13 Multiple Myeloma patient at low dose, 16 AL Amyloidosis patients presented at ASH 2024. b) US: 4 AL Amyloidosis patients.

Significant Near-Term Milestones

U.S. Ex- U.S.

Upcoming Milestones	Anticipated Timing
Next NXC-201 Program Update	1H 2025
Report interim clinical data readout for NEXICART-2 trial in AL Amyloidosis	2Q/3Q 2025
Report NXC-201 interim clinical data in unaddressed immune-mediated diseases	4Q 2025
Report final topline clinical data readout for NEXICART-2 trial in AL Amyloidosis	2Q/3Q 2026

Completed		
NASDAQ IPO 2021		✓
Formed Cell Therapy R&D taskforce in 2022		✓
Secured global commercial rights for NXC-201 from Hadassah/Bar-Ilan in 2022		✓
Reported NEXICART-1 AL Amyloidosis interim clinical data at:	ASGCT 2023	✓
	ASH 2023	✓
	ASGCT 2024	✓
	JCO 2024 / ASH 2024	✓
Dosed first US patient in NEXICART-2 AL Amyloidosis clinical trial		✓ Met mid '24 guidance
Reported NEXICART-2 AL Amyloidosis initial clinical data		✓ Met 4Q 2024 guidance

Pipeline: Only CAR-T in AL Amyloidosis; Tailor-Made for select Immune-Mediated Diseases

Lead Program: NXC-201, a next-generation BCMA-targeting CAR-T for AL Amyloidosis and select immune-mediated diseases

Indication	Therapy	Pre-clinical	Phase 1	Phase 2	Upcoming Milestones
Relapsed/Refractory AL Amyloidosis	NXC-201	US FDA and EU EC Orphan Drug Designation (ODD)			**2Q/3Q 2025:** Report interim clinical data readout for NEXICART-2 trial in AL Amyloidosis **2Q/3Q 2026:** Report final topline clinical data readout for NEXICART-2 trial in AL Amyloidosis
Undisclosed select Immune-Mediated Diseases	NXC-201	IND enabled			**4Q 2025:** Report NXC-201 interim clinical data in unaddressed immune-mediated diseases

Other Emerging Pipeline

Preclinical Candidates	Not yet announced	

NXC-201 Referenced in June 2024 New England Journal of Medicine Publication

The NEW ENGLAND JOURNAL of MEDICINE

REVIEW ARTICLE

Dan L. Longo, M.D., *Editor*

Systemic Light Chain Amyloidosis

Vaishali Sanchorawala, M.D.

TREATMENT OF RELAPSE AND PROGRESSION AFTER INITIAL THERAPY

No consensus has been established on the criteria for commencing second-line therapy in patients with progressive disease after initial therapy.[73,74] Patients with relapsed disease can be treated by repeating first-line therapy if the response lasted for more than a year, although such patients have a shorter time to relapse without a reduction in overall survival than patients who are treated with a different therapy for relapsed disease.

The potential options available for the treatment of relapsed systemic AL amyloidosis include proteasome inhibitors,[75,76] anti–CD-38 monoclonal antibodies,[77,78] immunomodulatory agents,[79] venetoclax for patients with t(11;14),[80] bendamustine,[81] high-dose melphalan with autologous SCT,[82,83] bispecific antibodies,[84,85] and even chimeric antigen receptor T-cell therapy.[86] Although it is not possible to be prescriptive regarding the sequencing of therapies, the two guiding considerations are the depth and duration of the initial response and the choice of a class of agents not previously used. The limitations imposed by a patient's reduced level of fitness or frailty and end-organ damage must also be considered. Enrollment in clinical trials is encouraged.



Figure 3. Therapeutic Landscape of AL Amyloidosis.

The therapeutic landscape of AL amyloidosis has seen substantial expansion in the past three decades. The majority of treatment regimens are adapted from myeloma therapies, with a focus on targeting the underlying plasma cell clone. Hematologic response has improved significantly with more effective and contemporary treatments, contributing to an overall increase in survival and a reduction in the rate of early death. CAR-T denotes chimeric antigen receptor T-cell therapy, CR complete hematologic response, CTD cyclophosphamide–thalidomide–dexamethasone, CyBorD cyclophosphamide–bortezomib–dexamethasone, HDM–SCT high-dose melphalan and stem-cell transplantation, Ixazomib–Dex ixazomib–dexamethasone, Len–Dex lenalidomide–dexamethasone, Mel–Dex melphalan–dexamethasone, Mel–P melphalan–prednisone, Pom–Dex pomalidomide–dexamethasone, Thal–Dex thalidomide–dexamethasone, and VGPR very good partial hematologic response.

tory AL amyloidosis: a multinational retrospective case series. Blood 2024;143:734-7.

86. Kfir-Erenfeld S, Asherie N, Grisariu S, et al. Feasibility of a novel academic ECMA-CART (HBI0101) for the treatment of relapsed and refractory AL amyloidosis. Clin Cancer Res 2022;28:5156-66.

87. Nuvolone M, Nevone A, Merlini G. Targeting amyloid fibrils by passive immunotherapy in systemic amyloidosis.

Footer Sanchorawala et al. Systemic Light Chain Amyloidosis. New England Journal of Medicine. June 2024.

World-Class Team

Management

Ilya Rachman, MD, PhD
Chief Executive Officer

Gabriel Morris, BA
Chief Financial Officer

Graham Ross, MBChB, FFPM
Chief Medical Officer

David Marks, MBBS, PhD
Chief Medical Officer,
Cell Therapy

Gerhard Bauer
Head of Cell Therapy
Manufacturing

Board of Directors

Helen Adams, CPA
Former Prometheus
Biosciences Board Member

Magda Marquet, PhD
ALMA Life Sciences

Jane Buchan, PhD
CEO, Martlet Asset
Management

Yekaterina Chudnovsky, JD
GI Research Foundation

Jason Hsu, PhD
Founder & Chairman,
Rayliant Global Advisors

Carey Ng, PhD
Mesa Verde Venture Partners

Scientific Advisory Board

Heather Landau, MD
Director, Amyloidosis Program

Suzanne Lentzsch, MD, PHD
Director, Multiple Myeloma
and Amyloidosis

Michaela Liedtke, MD
Co-Director, Stanford Amyloid
Center

Vaishali Sanchorawala, MD
Director, Amyloidosis Center

Marko Radic, PhD
Autoimmune CAR-T Pioneer

Gary Schiller, MD
UCLA Professor of Oncology

N-GENIUS Platform: Sterically-Optimized CAR-T Construct Drives Differentiated NXC-201 Clinical Profile

ALL BCMA CAR-TS ARE NOT CREATED EQUAL

N-GENIUS PLATFORM

Our CAR-T is differentiated based on 3 Key Construct Modifications

1 Proprietary Optimized CD3 – "CD3ζγ"

✓ Delivers "Digital" Intracellular Signaling

2 Proprietary Optimized CD8 Hinge Flexibility

✓ Reduces cytokine release

3 Proprietary Optimized COBRA Binder

✓ Enhances Plasma Cell Binding
✓ Ensures High Expression



Immix's proprietary N-GENIUS Platform can overcome the inherent limitations of conventional CAR-T methodologies that lack the sterically-optimized CD3ζγ ("Digital" Signaling), CD8 hinge flexibility, and COBRA binder, which drive NXC-201's greatly reduced neurotoxicity, minimized CRS duration, and enhanced efficacy in heavily pretreated patients

"Single amino acid substitutions at key sites can affect CAR-T function over 200-fold range"

Source: M. Assayag, et al. Academic BCMA-CART cells (HBI0101), a promising approach for the treatment of LC Amyloidosis. 27th Annual Meeting of The American Society of Gene and Cell Therapy (ASGCT). Late Breaking Oral Presentation. Baltimore, MD. May, 2024. Feucht, M. Sadelain, et al. Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency. Nature Medicine. 2019 Jan;25(1):82-88. doi: 10.1038/s41591-018-0290-5.Epub 2018 Dec 17. PMID: 30559421 PMCID: PMC6532069. O. Harush C. J. Cohen, et al. Preclinical evaluation and structural optimization of anti-BCMA CAR to target multiple myeloma. Haematologica. 2022 Oct 1;107(10):2395-2407. doi: 10.3324/haematol.2021.280169. PMID: 35354252 PMCID: PMC9521250. Adapted from PEGS 2021.

1 Proprietary Sterically-Optimized CD3ζ + CD8 Delivers “Digital” Intracellular Signaling, Eliminates Neurotoxicity, Reduces CRS Duration

CD3ζ

CARs rely on activation of CAR-T cells through CD3ζ derived immunoreceptor tyrosine-based activation motifs (ITAMs), typically 3 ITAM motifs per CAR

NXC-201 adds a positively charged amino acid (lysine) next to a tyrosine phosphorylation site, therefore:

- ✓ Impeding phosphorylation of ITAM1 (by affecting protein folding dynamics which block the tyrosine site), thus reducing intracellular reactivity
- ✓ Adding an additional site for ubiquitination, allowing the CAR to be marked for degradation more rapidly that a traditional CAR

The combined effect of these modifications is to drive a “digital” signaling of extracellular activity, that is on when antigen is present and off when not

Modification of ITAMs is a common theme in third-generation CAR design, with publications in Nature Medicine and by Memorial Sloan Kettering on the topic



nature Signal Transduction and Targeted Therapy

“In activated T cells, the CD3ζ chain gets ubiquitinated by CBLB at its multiple lysine residues and induces degradation of surface TCRs”

doi: 10.1038/s41392-021-00823-w

nature medicine

Memorial Sloan Kettering Cancer Center

“We hypothesized that the redundancy of CD28 and CD3ζ signaling in a chimeric antigen receptor (CAR) design incorporating all three CD3ζ immunoreceptor tyrosine-based activation motifs (ITAMs)11,13 may foster counterproductive T cell differentiation and exhaustion. Therefore, we calibrated ITAM activity by mutating tyrosine residues to impede their phosphorylation and downstream signaling”

doi: 10.1038/s41591-018-0290-5

Source: Feucht J, et al. Nat Med. 2019; Shah K, et al. Signal Transduct Target Ther. 2021

2 Proprietary Sterically-Optimized CD3ζ + CD8 Delivers "Digital" Intracellular Signaling, Eliminates Neurotoxicity, Reduces CRS Duration

CD8 Hinge

PreClinical

NXC-201: Optimized (Decreased) CD8 Hinge Flexibility Resulted In:

- ✓ >90% reduction in cytokine release in preclinical studies
- ✓ improved human efficacy
- ✓ zero neurotoxicity



IFNγ (pg/mL): K562-BCMA co-culture

Interferon-c (IFN-c) release after 24 h of co-culture of CAR T cells with BCMA+ (K562-BCMA, RPMI-8226, U266-B1, H929) targets.

Literature: Optimized (Decreased) CD8 Hinge Flexibility Resulted In

- ✓ >60% reduction in cytokine release in preclinical studies
- ✓ improved human efficacy
- ✓ zero neurotoxicity



IFNγ (pg/mL): K562-CD19 co-culture

CAR+ T cells were stimulated with K562 cells expressing human CD19. Supernatant was harvested after 24 hours of incubation, and the indicated cytokines were measured by cytokine bead array. Results are representative of two-to-four independent experiments.

Clinical

		Abecma in MM	NXC-201 in MM	Kymriah	CD19-BBz(86)
Efficacy	ORR (%)	72	92	52	73
	CR (%)	28	64	40	55
CRS	CRS, any grade (%)	85	95	58	28
	CRS, Grd3+ (%)	9	19	22	0
	Duration, CRS (days)	7	1 at 800M	7	n/a
Neurotoxicity	Neurotoxicity, any grades (%)	28	4% (all Grade 1-2)	21	0

Sterically-optimized (Decreased) CD8 Hinge Flexibility Results in Zero Neurotoxicity, Improved Human Efficacy, and reduction in CRS duration

MM: multiple myeloma

Source: E Lebel et al. Efficacy of HBI0101, an Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) for Relapsed/Refractory Multiple Myeloma. Abstract. ASH 2024. S Kfir-Erenfeld et al. Clinical evaluation and determinants of response to HBI0101 (BCMA CART) therapy in relapsed/refractory multiple myeloma. Blood Adv. 2024 Aug 13;8(15):4077-4088. doi: 10.1182/bloodadvances.2024012967. Ying Z, et al. Nat Med. 2019; Schuster SJ, et al. N Engl J Med. 2019; Assayag, M., et al EBMT 2023; Abecma FDA label; Harush O, et al. Haematologica. 2022; Friedman KM, et al. Hum Gene Ther. 2018. Kymriah: Preclinical is an average of CD8+ and CD4+ T-cells, source: Milone MC, et. Al. Mol Ther. 2009 Aug;17(8):1453-64. doi: 10.1038/mt.2009.83. Epub 2009 Apr 21. Erratum in: Mol Ther. 2015 Jul;23(7):1278. PMID: 19384291; PMCID: PMC2805264. *1 Day CRS occurred in high dose MM cohort as of EBMT 2023. NXC-201 in multiple myeloma data from ASH 2023 95% ORR in patients without prior anti-BCMA therapy exposure

3 Sterically-Optimized COBRA Binder Ensures High Expression And Binding Affinity

COBRA Binder

COBRA Binder Leads with Heavy Chain



doi: 10.3389/fonc.2023.1200914

Proven Linker of Heavy and Light Chain Employed

Biomarker Research

"Glycine (Gly) and serine (Ser) residues provide the flexibility necessary for antigen-binding sites to change conformation and maintain good stability in aqueous solutions… prevent[ing] formation of secondary structures and reduc[ing] likelihood of the linker interfering with the folding and function of the scFv"

September 19, 2022
doi: 10.1186/s40364-022-00417-w

NXC-201
COBRA Binder: Heavy Chain – Proven Linker – Light Chain Configuration, enabling:

- ✓ Rapid, Sustained CAR-T Expansion
- ✓ Improved Cytotoxicity in the presence of antigen

Source: Moreno-Cortes E,. et al Front Oncol. 2023; Mazinani M, et al. Biomark Res. 2022.

AL Amyloidosis: ~33,000 Relapsed/Refractory U.S. Patients with No FDA Approved Drugs

NXC-201 TARGETS AL AMYLOIDOSIS PLASMA CELLS THAT EXPRESS BCMA ON CELL SURFACE

Light chains produced by dysfunctional plasma cells in bone marrow

Light chains misfold and aggregate

Light chains deposit in organs, damaging organs

Bone marrow plasma cells



NXC-201 TARGETS BCMA RECEPTOR ON PLASMA CELLS, ELIMINATING SOURCE OF LIGHT CHAINS

BCMA receptor

Light chains

Sheet of misfolded light chains (amyloid)



Heart

- Heart failure
- Dangerous, irregular heart rhythms
- Difficulty breathing
- Low blood pressure

Kidney

- Kidney failure
- Elevated protein in the urine
- Swelling of the limbs

Liver

- Enlarged liver
- Abnormal enzyme levels

Bone marrow | **Circulation** | **Target tissues**

Source: Merlini, G., et al. Nat Rev Dis Primers. Oct 2018, Front. Cardiovasc. Med., Dec 2022, Hemato 2022, 3(1), 47-62; https://doi.org/10.3390/hemato3010005 . Quock TP, Yan T, Chang E, Guthrie S, Broder MS. Epidemiology of AL amyloidosis: a real-world study using US claims data. Blood Adv. 2018 May 22;2(10):1046-1053. doi: 10.1182/bloodadvances.2018016402. PMID: 29748430; PMCID: PMC5965052.Staron A, et al. Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history study. Blood Cancer J. 2021;11(8):139; Lu R, Richards TA. AL Amyloidosis: Unfolding a Complex Disease. J Adv Pract Oncol. 2019;10(8):813-825.

NXC-201 Addresses Sizable U.S. Relapsed/Refractory AL Amyloidosis Patient Population (1/2)

Newly Diagnosed

Relapsed/Refractory

Newly diagnosed
US Incidence ~4,300

Johnson & Johnson
DARZALEX (daratumumab)

Darzalex Combination
(combined with cyclophosphamide, bortezomib, and/or dexamethasone)
Weekly treatments
[FDA approved 2021]

1L SOC: 12 - 21 months median duration on therapy

prothena
NASDAQ:PRTA
Birtamimab
(combined with Darzalex, cyclophosphamide, bortezomib, and/or dexamethasone)
[clinical trial]

AstraZeneca
CAELUM BIOSCIENCES
CAEL-101
Weekly Treatments
Mayo Stage IIIb only
(combined with Darzalex, cyclophosphamide, bortezomib, and/or dexamethasone)
[clinical trial]

Relapsed/Refractory
~2,649

Estimated relapsed/refractory
US Prevalence ~33,277 in 2024 (Previously Treated)

Eligible R/R ALA Patients ~35,926

NXC-201 – 75% (12/16) Complete Response rate at ASH 2024 (JCO 2024)
One-time treatment | Monotherapy | Relapsed/Refractory ALA Patients
34,489 Eligible U.S. AL Amyloidosis Patients

Relapsed/Refractory

Blue Ocean Opportunity
No FDA Approved Drugs in Relapsed / Refractory AL Amyloidosis

Note: Public information development plans as of 2023. Dara-CyBorD: Daratumumab, Bortezomib + cyclophosphamide + dexamethasone. BMD: bortezomib, melphalan, and dexamethasone. Source: Dima D, et al. Diagnostic and Treatment Strategies for AL Amyloidosis in an Era of Therapeutic Innovation. JCO Oncol Pract. 2023; Jimenez-Zepeda VH, et al. Understanding real-world treatment patterns and clinical outcomes in AL amyloidosis patients diagnosed in Canada: A population-based cohort study. EJHaem. 2022; Bou Zerdan M, et al. Systemic AL amyloidosis: current approach and future direction. Oncotarget. 2023; Kumar S, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol. 2012; Browning S, et al. Hematologic relapse in AL amyloidosis after high-dose melphalan and stem cell transplantation. Blood. 2017; Palladini G, et al. Presentation and outcome with second-line treatment in AL amyloidosis previously sensitive to nontransplant therapies. Blood. 2018; Quock TP, Yan T, Chang E, Guthrie S, Broder MS. Epidemiology of AL amyloidosis: a real-world study using US claims data. Blood Adv. 2018 May 22;2(10):1046-1053. doi: 10.1182/bloodadvances.2018016402. PMID: 29748430; PMCID: PMC5965052.Staron A, et al. Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history study. Blood Cancer J. 2021;11(8):139; Lu R, Richards TA. AL Amyloidosis: Unfolding a Complex Disease. J Adv Pract Oncol. 2019;10(8):813-825. EQ Crusoe, E Kastritis, V Sanchorawala, GMOBOTAS Group. Subcutaneous Daratumumab + Bortezomib, Cyclophosphamide, and Dexamethasone (Vcd) in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: Updated Results from the Phase 3 Andromeda Study. Hematology, Transfusion and Cell Therapy. Volume 43, Supplement 1, 2021. https://doi.org/10.1016/j.htct.2021.10.364. 21-month duration: Kastritis E, et al. 891 Subcutaneous Daratumumab (DARA) + Bortezomib, Cyclophosphamide, and Dexamethasone (VCd) in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: Overall Survival and Final Major Organ Deterioration Progression-Free Survival Results from the Phase 3 Andromeda Study. Abstract. ASH 2024. Bellofiore C, et al. 12-month duration: A real-life study of daratumumab combinations in newly diagnosed patients with light chain (AL) amyloidosis. Hematol Oncol. 2024.

NXC-201 Addresses Sizable U.S. Relapsed/Refractory AL Amyloidosis Patient Population (2/2)



Source: Incidence and prevalence: Quock T et al, Epidemiology of AL amyloidosis: a real-world study using US claims data. Blood 2018. Incidence growth rate: Laires P et al, Prevalence, Incidence, and Characterization of LIGHT Chain Amyloidosis in the USA: A Real-World Analysis Utilizing Electronic Health Records (EHR). Blood 2023. Daratumumab: Bellofiore C, et al. A real-life study of daratumumab combinations in newly diagnosed patients with light chain (AL) amyloidosis. Hematol Oncol. 2024. Palladini G et al, Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA. Blood. 2020. ASCT: Bomsztyk J et al, Recent guidelines for high-dose chemotherapy and autologous stem cell transplant for systemic AL amyloidosis: a practitioner's perspective. Expert Review of Hematology 2022. Gustine J et al, Predictors of hematologic response and survival with stem cell transplantation in AL amyloidosis: A 25-year longitudinal study. AJH 2022. Mayo staging: Zanwar S, et al. Treatment patterns for AL amyloidosis after frontline daratumumab, bortezomib, cyclophosphamide, and dexamethasone treatment failures. Leukemia 2024.

NXC-201 May Be a Curative Treatment for AL Amyloidosis

ALL BCMA CAR-TS ARE NOT CREATED EQUAL

AL amyloidosis is caused by dysfunctional plasma cells that can live for years, continuously producing toxic, misfolded amyloid light chain antibody fragments

AL Amyloidosis disease-causing plasma cells:

- Are a minority of total plasma cells
- Are 1 of thousands of antibody-specific plasma cells, each of which produces 1 antibody, specific to 1 target (e.g. common flu, cold, a type of bacteria…)
- Are eliminated by NXC-201 treatment

Then healthy plasma cells regenerate in the months after NXC-201 treatment, potentially preventing disease relapse



Source: Alberts B, Johnson A, Lewis J, et al. Molecular Biology of the Cell. 4th edition. New York: Garland Science; 2002. The Generation of Antibody Diversity. Available from: https://www.ncbi.nlm.nih.gov/books/NBK26860/; Wang Y, Li C, Xia J, Li P, Cao J, Pan B, Tan X, Li H, Qi K, Wang X, Shi M, Jing G, Yan Z, Cheng H, Zhu F, Sun H, Sang W, Li D, Zhang X, Li Z, Zheng J, Liang A, Zhou J, Xu K. Humoral immune reconstitution after anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma. Blood Adv. 2021 Dec 14;5(23):5290-5299. doi: 10.1182/bloodadvances.2021004603. PMID: 34587230; PMCID: PMC9153033.

NXC-201 Designed for High Activity Against Disease-causing AL Amyloidosis Plasma Cells

ALL BCMA CAR-TS ARE NOT CREATED EQUAL

a) Uneven BCMA expression and b) frail patient condition has historically prevented conventional, approved CAR-T use in AL Amyloidosis
NXC-201 was designed and tested for human AL Amyloidosis treatment, with preclinical testing revealing that:

1 BCMA is expressed in 18 AL Amyloidosis patients at a low-medium level…



2 …NXC-201 CAR-Ts are activated in presence of the AL Amyloidosis target cells…



…completely eliminating AL Amyloidosis aberrant plasma cells from patient bone marrow.



NXC-201's uniquely favorable tolerability profile (no neurotoxicity + "Single-day CRS") combined with proven preclinical and clinical efficacy make NXC-201 uniquely suited to treat AL Amyloidosis.

Note: NXC-201 (formerly NBI0101). Infy TNFa for two patients, AL1, AL2. Far right top right quartile selected diseased AL Amyloidosis plasma cell elimination. Far right graph after 33 days co-incubated with NXC-201.
Source: Kfir-Erenfeld S, et al. Feasibility of a Novel Academic BCMA-CART (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis. Clin Cancer Res. 2022; Raje N, et al. Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2019.;

NXC-201 N-GENIUS Platform "Single-Day CRS" Drives AL Amyloidosis Leadership

ALL BCMA CAR-TS ARE NOT CREATED EQUAL

NXC-201's short CRS duration makes it **uniquely suitable to treat ALA patients** (in whom the #1 source of mortality is heart failure)

Cardiovascular stress is the key determinant for ability to treat relapsed/refractory ALA patients

- Long CRS duration causes extended cardiovascular stress
- Other CARTs have 4-8x longer CRS duration

"The biggest challenge … has been applicability of these therapies in amyloidosis **when the patients are particularly frail and have organ dysfunction** … where the key lies in the safety rather the efficacy in a low-volume disease setting is going to be key … "

– *Dr. Susan Bal, MD*
Assistant Professor, Hematology
University of Alabama at Birmingham



Data in Multiple Myeloma

Source: M. Assayag, et al. Point-of-care CART manufacture and delivery for the treatment of multiple myeloma and AL amyloidosis: the experience of Hadassah Medical Center. European Society for Blood and Marrow Transplantation 49th Annual Meeting. Poster Presentation. April 2023. Nov 2023 KOL discussion https://lifescievents.com/event/immixbio/;NXC-201 (formerly HBI0101) American Society of Hematology Presentation, Abecma FDA approval label, Carvykti FDA approval label, Arcelx S-1. NXC-201 data from NEXICART-1 clinical study.

Overcoming Neurotoxicity

ALL BCMA CAR-TS ARE NOT CREATED EQUAL



Source: Carvykti and Abecma FDA labels, Arcellx S-1. Assayag, et al. Academic BCMA-CART cells (HBI0101), a promising approach for the treatment of LC Amyloidosis. 27th Annual Meeting of The American Society of Gene and Cell Therapy (ASGCT). Late Breaking Oral Presentation. Baltimore, MD. May, 2024 Assayag, N., et al. European Society for Blood and Marrow Transplantation 49th Annual Meeting. Lebel E, et al. Efficacy and Safety of a Locally Produced Novel Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) (HBI0101) for the Treatment of Relapsed and Refractory Multiple Myeloma, International Myeloma Society 20th Annual Meeting. 2023. Differences exist between trial designs and subject characteristics, and caution should be exercised when comparing data across studies. Figures reflect cross-trial comparison and not results from a head-to head study. Kyverna corporate presentation June 14, 2024. Accessed through https://www.sec.gov/ix?doc=/Archives/edgar/data/0001994702/000095017024073312/kytx-20240614.htm. Low volume diseases refers to ANCA vasculitis, autoimmune encephalitis, anti-synthetase syndrome, CIDP, DAGLA encephalitis, IgG4 related disease, Lambert-Eaton myasthenic syndrome, lupus nephritis, myasthenia gravis, multiple sclerosis, rheumatoid arthritis, systemic sclerosis, Stiff Person syndrome Cabaletta 2Q 2024 earnings press release: https://www.cabalettabio.com/investors/news-events/press-releases/detail/114/cabaletta-bio-reports-second-quarter-2024-financial-results. High volume disease NXC-201 CRS data from ASH 2024 Abstract which included 84 MM patients. NXC-201 data from NEXICART-1 clinical study.

U.S. NEXICART-2 Trial Designed Based on ex-US NEXICART-1 Trial Experience

NXC-201 clinical data indicate that R/R Amyloidosis patients with preserved heart function are more likely to benefit from treatment

Relapsed/Refractory AL Amyloidosis NXC-201 trial	Allows pre-existing severe cardiac patient enrollment?	Allows patients with prior BCMA-targeted therapy exposure?	Allows patients with concomitant Multiple Myeloma?
NEXICART-1: ongoing Israel trial	X Yes	X Yes	X Yes
NEXICART-2: ongoing US trial	✓ No	✓ No	✓ No

NEXICART-2: 40 patient, single-arm, multi-site, US trial → submit data to FDA

Source: Feasibility of a Novel Academic Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis, 65th ASH Annual Meeting and Exposition, San Diego, CA. October 2023. R. Chakraborty, et al. Safety and efficacy of teclistamab in systemic immunoglobulin light chain amyloidosis. Blood Cancer Journal. October 2023. N. Forgeard, et al. Teclistamab in relapsed or refractory AL amyloidosis, a multinational retrospective case series. Blood. February 2024. One NXC-201 relapsed/refractory AL amyloidosis patient died of COVID-19

NEXICART-2: US

CAR-T NXC-201 Clinical Trial

IMMIX BIOPHARMA

NEXICART-2 U.S. Relapsed/Refractory AL Amyloidosis Trial (NCT06097832)

NEXICART-2 NXC-201 TRIAL INITIATED IN MID-2024

Study design

- Open-label, single-arm Phase 1b/2 study
- n=40 patients (majority of which expected to be enrolled in Phase 2 portion)

Key criteria

Inclusion	• AL Amyloidosis patients exposed to at least 1 line of therapy including a CD38 monoclonal antibody
Exclusion	• Prior anti-BCMA directed therapy • Cardiac: Mayo stage 3b, NYHA stage III/IV • Concomitant Multiple Myeloma

Outcome measures

- Phase 1b:
  - Safety
  - Efficacy: Complete Response according to consensus recommendations in AL amyloidosis
- Phase 2:
  - Efficacy: Complete Response according to consensus recommendations in AL amyloidosis
  - Safety

Status

- Lead site Memorial Sloan Kettering and other US sites started mid-2024

*Dosing informed by NEXICART-1 Israel trial in which Complete Responses in light chain Amyloidosis were observed at all dose levels: 150M, 450M

Relapsed/Refractory AL Amyloidosis NXC-201 trial	Allows pre-existing severe cardiac patient enrollment?	Allows patients with prior BCMA-targeted therapy exposure?	Allows patients with concomitant Multiple Myeloma?
NEXICART-1: ongoing Israel trial	X Yes	X Yes	X Yes
NEXICART-2: ongoing US trial	✓ No	✓ No	✓ No

Company believes NEXICART-2 patients are most likely to benefit from NXC-201 therapy

Note: Complete Response according to consensus recommendations in AL amyloidosis (Palladini, et al. 2012."Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis." Leukemia 26(11): 2317-2325.)

NEXICART-2: Patient enrollment focused on patients with preserved heart function

Preserved heart function

Patient #	NX2-001	NX2-002	NX2-003	NX2-004	Median (range)
Age	56	67	82	64	66 (56-82)
Gender	Female	Female	Male	Female	-
Prior lines of therapy	4	6	2	4	4 (2-6)
Follow up (days)	141	113	57	29	85 (29-141)
dFLC (mg/L)	65	24	-	86	65 (24-86)
M-Spike (g/dL, if dFLC not inclusion criteria)	-	-	0.79	-	-
FISH cytogenetics	1q21+	1q21+	1q21+	-	-
Organ involvement	Heart	Heart	Kidney	Heart	-
NYHA stage	I	II	I	I	-
NT-ProBNP (pg/mL)	146	560	1,297	218	389 (146-1,297)
hs-Troponin-I (ng/L)	7	6	42	7	7 (6-42)
Creatinine (mg/dL)	0.7	1.1	2.2	1.8	1.5 (0.7-2.2)
Albuminuria (mg/24 hrs)	143	0	3,032	10	77 (0-3,032)
Alk Phos (U/L)	94	40	73	83	78 (40-94)
MAYO stage	Stage II	Stage II	Stage II	Stage IIIA	-

Note: Data cut-off as of November 14, 2024. For patient NX2-001, prior lines of therapy included 1) Cyclophosphamide/bortezomib, dexamethasone, 2) ASCT, 3) Bortezomib/ dexamethasone, 4) Isatuximab. For patient NX2-002, prior lines included 1) Bortezomib/dexamethasone, 2) ASCT, 3) Bortezomib/dexamethasone, 4) Daratumumab, 5) Pomalidomide and dexamethasone, 6) Melphalan. For patient NX2-003, prior lines included 1) Daratumumab, 2) Bortezomib/ Velcade. For patient NX2-004, prior lines included 1) Bortezomib, 2) Dexamethasone, 3) Dara CyBorD, 4u) Daratumumab.

NEXICART-2 Efficacy: Rapid Normalization of Diseased Light Chains within First ~Month; Consistent with Ex-US Dataset



The NEW ENGLAND JOURNAL of MEDICINE

"An early and deep hematologic response has been found to lead to significantly prolonged survival"

– *Vaishali Sanchorawala, M.D.*
Professor, Hematology and Oncology
Director, Amyloidosis Center at Boston University School of Medicine
Director, Stem Cell Transplantation at Boston Medical center

doi: 10.1056/NEJMra2304088

Note: Data cut-off as of November 14, 2024. Vein-to-vein time was 12 days for patients NX2-001, NX2-002, NX2-003, NX2-004. dFLC: difference in free light chain (disease marker). Complete response according to consensus recommendations for AL Amyloidosis treatment response criteria (Palladini, 2012).

NEXICART-2 Efficacy: Rapid Normalization of Diseased Light Chains within First ~Month; Consistent with Ex-US Dataset

	Subject #	NX2-001	NX2-002	NX2-003	NX2-004
	NXC-201 Dose (million CAR+T cells)	150	150	150	450
AL Amyloidosis Disease Markers	Status as of data cutoff	Normal	Normal	Normal	Normal
	Time to normalization (days)	26	7	15	7
	Response Status	**CR**	Pending (already MRD(-)10^{-6})	**CR**	Pending (already MRD(-)10^{-6})



Note: Data cut-off as of November 14, 2024. Vein-to-vein time was 12 days for patients NX2-001, NX2-002, NX2-003, NX2-004. dFLC: difference in free light chain (disease marker). Complete response according to consensus recommendations for AL Amyloidosis treatment response criteria (Palladini, 2012).

NEXICART-2 Efficacy: Complete Responses in Two Patients and Remaining Two MRD- 10^{-6}; All Patients in Ongoing Response as of Data Cut-off

	1	2	3	4
CART cells infused ($x10^6$)	150	150	150	450
Best hematologic response	CR	Pending already MRD(-)10^{-6}	CR	Pending already MRD(-)10^{-6}
Follow-up (months)	141	113	57	29
Best MRD	Neg 10^{-6}	Neg 10^{-6}	Pos 10^{-6}	Neg 10^{-6}

Complete response (CR) is FDA Regulatory Endpoint



[1] MAYO staging

Note: Data cut-off as of December 17, 2024. Premkumar VJ, et al. Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis. Blood Cancer J. 2021 Jan 11;11(1):10. doi: 10.1038/s41408-020-00397-w. PMID: 33431806; PMCID: PMC7801694.Theodorakakou F, et al. Outcomes of patients with light chain (AL) amyloidosis after failure of daratumumab-based therapy. Br J Haematol. 2023 Nov;203(3):411-415. doi: 10.1111/bjh.19042. Epub 2023 Aug 14. PMID: 37580907.

NEXICART-2 Safety: Consistent or Improved Compared to Ex-US Dataset

- No ICANS neurotoxicity of any kind
- Grade 2 CRS in one patient, Grade 1 CRS in one patient, both with 1 day duration

Patient #	NX2-001	NX2-002	NX2-003	NX2-004
CART Cell Dose ($x10^6$)	150	150	150	450
Neurotoxicity	**None**	**None**	**None**	**None**
Cytokine release syndrome (CRS)	**None**	**None**	Grade 2	Grade 1
CRS Onset (days)	-	-	3	3
CRS Duration (days)	-	-	1	1
Neutropenia	Grade 3	Grade 3	Grade 3	Grade 4
Febrile Neutropenia	None	None	None	None
Anemia	Grade 1	Grade 2	Grade 3	Grade 1
Thrombocytopenia	Grade 1	Grade 1	None	Grade 1
Acute kidney failure	None	None	None	None
Liver Function Test Abnormalities	Grade 2	None	None	None
Serious Infections	None	None	None	None
Fatigue	None	None	None	None

Note: Data cut-off as of November 14, 2024. CRS and ICANS reported according to ASTCT Consensus Grading (Lee et al. 2019). 001-004 Grade 4 Neutropenia duration of one day. Patient NX2-004 neutropenia to be updated subsequently.

NEXICART-2: Drivers of Complete Response (CR) in relapsed/refractory AL Amyloidosis



Single-arm potentially pivotal NEXICART-2 trial designed considering NEXCIART-1 and precedents in AL

		2021 daratumumab (DARZALEX) FDA Approval	NXC-201 NEXICART-2
Patient Characteristics	Line of Therapy	Newly Diagnosed	Relapsed/Refractory
	Standard of Care (SoC) at time of trial	3-drug combination: Cyclophosphamide, bortezomib, dexamethasone	✓ **None (no FDA approvals)**
	Randomization vs. Standard of Care?	x **Randomization vs. SoC**	✓ **No SoC to randomize against**
	Lines of therapy prior to receiving study drug	x **None**	✓ **At least 1 line of therapy including a CD38 monoclonal antibody**
Study Design	Statistical Power	Based on the assumption that the percentage of patients with a hematologic complete response would be 15 percentage points higher in the daratumumab group than in the control group; approximately **360 patients were required** to provide 85% power to detect this difference (two-sided alpha level of 0.05).	Based on NEXICART-1 complete response (CR) rates, with a sample size of **40 patients**, there is a >99% probability that the lower limit of 95% CI for the NXC-201 CR rate is statistically significantly higher compared to historical controls based on the Clopper-Pearson exact method.
	Primary Endpoint	✓ **Hematologic complete response rate for both studies**	

Single-arm, open-label FDA approval precedents include: Abecma/BMS (single arm study 100 patients in efficacy results population, FDA approved 2021); Carvykti/J&J (single arm study 97 patients in efficacy results population, FDA approved 2022); Elrexfio/Pfizer (single arm study 97 patients in efficacy results population, FDA approved 2023)

Note: Source for daratumumab information is ANDROMEDA (NCT03201965). NXC-201 information on this slide is illustrative only and represents current plan.

NEXICART-1: Ex-US

CAR-T NXC-201 Clinical Trial

IMMIX BIOPHARMA

NEXICART-1: Normalization of Diseased Free Light Chains 30 Days after Dosing

NXC-201 RAPIDLY ELIMINATES DISEASED AL AMYLOIDOSIS PLASMA CELLS AND EXITS WITHIN ~30 DAYS



(Each line represents 1 patient clinical data readout after NXC-201)

The NEW ENGLAND JOURNAL of MEDICINE

"An early and deep hematologic response has been found to lead to significantly prolonged survival"

– *Vaishali Sanchorawala, M.D.*
Professor, Hematology and Oncology
Director, Amyloidosis Center at Boston University School of Medicine
Director, Stem Cell Transplantation at Boston Medical center

doi: 10.1056/NEJMra2304088

Note: Data cut-off as of December 9, 2024. E Lebel et al. Efficacy and Safety of Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) for the Treatment of Relapsed and Refractory AL Amyloidosis. Presentation. ASH 2024.

NEXICART-1: 6 patients had pre-existing heart failure; 10 patients had preserved heart function

PRE-EXISTING HEART FAILURE CAUSES PHYSICALLY IRREVERSIBLE DISTORTION OF HEART STRUCTURE, SHAPE AND SIZE

Preserved heart function Pre-existing heart failure

Patient #	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	Median (range)
Age	64	58	82	63	64	72	55	68	78	59	64	64	63	67	70	58	64 (55-82)
Gender	Male	Female	Male	Male	Male	Female	Female	Male	Male	Male	Female	Male	Female	Male	Male	Male	11/16 M 5/16 F
dFLC (mg/L)	143	177	50	550	51	103	196	408	41	108	64	129	83	275	49	86	106 (41-550)
BMPCs (%)	3	15	1	15	0.1	1	1	10	15	1	1	1	0.5	1.5	0.5	0.3	1 (0.1-15)
FISH cytogenetics	t(11:14)	t(14:16) 1Q+	14Q-	t(11:14)	t(11:14)	t(11:14) 1Q+	14Q-	17p-	Normal	17p-	t(4:14) 1Q+	t(11:14)	t(11:14)	Normal	t(11:14)	Normal	7/16 (44%) t(11:14)
Organ involvement	Cardiac, Renal, PNS	Cardiac, Renal, Liver	Renal, GI	Cardiac, Liver, Lung, Soft tissue, PNS	Cardiac, Soft tissue, PNS	Cardiac, Renal, Liver	Cardiac, Soft tissue	Cardiac, Renal, Soft tissue	Renal	Cardiac, Renal, PNS	Cardiac, Renal, GI, Liver, Soft tissue, PNS	Cardiac, Renal	Cardiac, Renal, Soft tissue, GI	Liver	Cardiac, PNS, GI	Cardiac, Renal, GI, Liver	Heart: 13/16 (81%) Kidney: 11/16 (69%) Liver: 6/16 (38%)
NYHA stage	3	4	1	3	2	4	4	2	1	2	2	1	2	3	2	2	1-2: 10/16 (38%) 3: 3/16 (19%) 4: 3/16 (19%)
ProBNP (pg/ml)	7,500	2,008	119	2,773	731	28,000	6,600	220	930	669	211	3,158	281	191	107	964	831 (107-28,000)
Trop T (ng/L)	60	40	8	78	18.3	110	30	12	9	8	20	--	--	--	--	--	--
Creatinine (mmol\L)	80	72	110	100	82	108	83	69	220	227	79	--	--	--	--	--	--
Albuminuria (g/24h)	0.3	0.3	2.4	0.1	0.1	1.0	0	0	0.3	1.4	0	--	--	--	--	--	--
ALKP (u/L)	45	218	84	140	84	186	166	106	160	59	160	--	--	--	--	--	--
MAYO stage	3a	3a	1	3a	2	3b	2	1	1	2	2	3a	1	1	1	2	--
ECOG PS	0	2	0	0	1	2	4	0	1	1	1	1	1	2	0	1	1 (0-4)
Concomitant MM	Yes	no	no	No	yes	no	No	no	no	no	no	no	no	no	no	no	2/16
Compassionate use	No	no	no	yes	no	no	yes	no	no	no	no	no	no	no	no	no	2/16

Note: Data cut-off as of December 9, 2024. E Lebel et al. Efficacy and Safety of Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) for the Treatment of Relapsed and Refractory AL Amyloidosis. Presentation. ASH 2024. Eyal Lebel et al., Efficacy and Safety of Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor T-Cell for the Treatment of Relapsed and Refractory AL Amyloidosis. JCO 0, JCO-24-02252. DOI:10.1200/JCO-24-02252.

NEXICART-1 NXC-201 Produces Durable Complete Responses in Patients with Preserved Heart Function

Duration of response (ASH 2024)



sCR: strict complete response, CR: complete response

Note: E Lebel et al. Efficacy and Safety of Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) for the Treatment of Relapsed and Refractory AL Amyloidosis. Presentation. ASH 2024. Exclusion criteria: Mayo Stage 3b, NYHA 3/4, prior BCMA exposure. Patient 9 death due to depression. Eyal Lebel et al., Efficacy and Safety of Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor T-Cell for the Treatment of Relapsed and Refractory AL Amyloidosis. JCO 0, JCO-24-02252. DOI:10.1200/JCO-24-02252.

NEXICART-1: 75% Complete Response Rate (is the FDA Regulatory Endpoint)

Preserved heart function Pre-existing heart failure

Patient #	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16
CART cells infused ($\times 10^6$)	150	450	800	450	800	800	800	800	800	800	800	800	800	800	800	800
Best hematologic response	CR	CR	CR	CR	CR	VGPR	PR	VGPR	CR	CR	PD	CR	CR	CR	CR	CR
Follow-up (months)	10.3	10.2	31.5, ongoing	4.0	24.0, ongoing	3.3	3.8	5.5	6.0	8.7, ongoing	1.3	6.2, ongoing	4.2, ongoing	2.2, ongoing	2.0, ongoing	1.5, ongoing

Complete response (CR) is FDA Regulatory Endpoint

- **75% (12/16) Complete Response (CR) rate** (9 out of 16 were MRD- 10^{-5})
- Best responder: 31.5 months complete response ongoing as of December 9, 2024 cut-off
- Historical complete response rates for investigator's choice is ~3-20%

Note: Data cut-off as of December 9, 2024. E Lebel et al. Efficacy and Safety of Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) for the Treatment of Relapsed and Refractory AL Amyloidosis. Presentation. ASH 2024. Follow-up duration, estimated internally based on ASH 2024 published swimmer plot. Premkumar VJ, et al. Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis. Blood Cancer J. 2021 Jan 11;11(1):10. doi: 10.1038/s41408-020-00397-w. PMID: 33431806; PMCID: PMC7801694. Theodorakakou F, et al. Outcomes of patients with light chain (AL) amyloidosis after failure of daratumumab-based therapy. Br J Haematol. 2023 Nov;203(3):411-415. doi: 10.1111/bjh.19042. Epub 2023 Aug 14. PMID: 37580907. Eyal Lebel et al., Efficacy and Safety of Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor T-Cell for the Treatment of Relapsed and Refractory AL Amyloidosis. JCO 0, JCO-24-02252. DOI:10.1200/JCO-24-02252.

NXC-201: Potential to Expand to Select Immune-Mediated Diseases

CAR-T NXC-201 Targets Plasma Cells (antibody factories of the body)

ANTIBODY FACTORY PLASMA CELLS PRODUCE ANTIBODIES THAT DRIVE IMMUNE-MEDIATED DISEASES

AL Amyloidosis



Infiltrates and damages heart

AL amyloid antibody deposits

Light chain antibody fragments

Neurology

- Myasthenia Gravis
- NMO Spectrum Disorder

Hematology

- Thrombotic thrombocytopenic purpura
- Immune Thrombocytopenia

Rheumatology

- Systemic Lupus Erythematosus
- Rheumatoid Arthritis

Vascular

- ANCA vasculitis

Disease-causing antibodies

ANTIBODY FACTORY PLASMA CELL

(NXC-201 therapeutic target)

Note: select indications noted above are for illustrative purposes only.

*Illustrative list of immune-mediated diseases where B cells may play a role in initiating or maintaining disease, and where NXC-201 may provide a potential treatment

Source: MedicTests. Lee, J. et al. Antigen-specific B cell depletion for precision therapy of mucosal pemphigus vulgaris. J. Clin. Invest. 2020. Mackensen, A. et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat. Med. 2022. Qin C, et al. Anti-BCMA CAR T-cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis optica spectrum disorders: phase 1 trial interim results. Signal Transduct Target Ther. 2023. Granit V, et al. Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non randozised phase 1b/2a study. Lancet Neurol. 2023. McGlothlin J, et al. Bortezomib and daratumumab in refractory autoimmune hemolytic anemia. Am J Hematol. 2023. Yu TS, et al. Abnormalities of bone marrow B cells and plasma cells in primary immune thrombocytopenia. Blood Adv. 2021. Zhang Z, Xu Q, Huang L. B cell depletion therapies in autoimmune diseases: Monoclonal antibodies or chimeric antigen receptor-based therapy? Front Immunol. 2023. Pioli PD. Plasma Cells, the Next Generation: Beyond Antibody Secretion. Front Immunol. 2019

NXC-201 BCMA CAR-T targeting is uniquely suited to address Immune-Mediated Diseases

NXC-201 BCMA CAR-T TARGETS LONG-LIVED PLASMA CELLS, WHICH ARE OFF-TARGET FOR CD19 THERAPEUTICS



~80% of all antibodies are produced by plasma cells…

BCMA is expressed on long lived plasma cells

NXC-201 BCMA CART targets long lived plasma cells (LLPC), targeting the source of disease-causing antibodies

- CD19 therapies target earlier lineage B-Cells, allowing LLPCs to persist

Immix Biopharma unaddressed IMD indication selection criteria

High unmet medical need	✓
Limited therapies in development	✓
Biological basis for plasma cell-mediated therapy	✓

Appendix

February 2025

Advantages of CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis

		NXC-201	Antibody-drug conjugates	Bispecifics
1	One-time treatment	✓	✗	✗
2	High Complete Response Rates	✓	✗	✗
3	Low rates of severe infection	✓	✓	✗
4	No ICANS/Neurotoxicity	✓	✓	✗

NXC-201 uniquely suited for Relapsed/Refractory AL Amyloidosis

Note: High complete response rates defined as >50%. Low rates of severe infection refers to <30%

Source: Feasibility of a Novel Academic Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis, 65th ASH Annual Meeting and Exposition, San Diego, CA. October 2023. R. Chakraborty, et al. Safety and efficacy of teclistamab in systemic immunoglobulin light chain amyloidosis. Blood Cancer Journal. October 2023. N. Forgeard, et al. Teclistamab in relapsed or refractory AL amyloidosis, a multinational retrospective case series. Blood. February 2024. Chakraborty R, Bhutani D, Maurer MS, Mohan M, Lentzsch S, D'Souza A. Safety and efficacy of teclistamab in systemic immunoglobulin light chain amyloidosis. Blood Cancer J. 2023 Nov 27;13(1):172. doi: 10.1038/s41408-023-00950-3. PMID: 38012151; PMCID: PMC10682473. One NXC-201 relapsed/refractory AL amyloidosis patient died of COVID-19. Kastritis, et al. Efficacy And Safety Of Belantamab Mafodotin Monotherapy In Patients With Relapsed Or Refractory Light-chain Amyloidosis: A Phase 2 Study By The European Myeloma Network. Abstract. EHA 2024.

In AL Amyloidosis, NXC-201 Overcomes Limitations of Other Modalities in Performance and Tolerability

Challenges of bispecifics/ T-cell engagers	NXC-201 overcomes these challenges
• No clinical trials with clinical data available in relapsed/refractory AL amyloidosis	✓ **75% CR in relapsed/refractory AL amyloidosis**
• Early data from select centers indicates bispecific responses and tolerability are inferior to CAR-T (NXC-201) in relapsed/refractory AL amyloidosis	✓ **0 deaths from infection in relapsed/refractory AL amyloidosis**
• Retrospective study with 17 R/R multiple myeloma + AL Amyloidosis patients: ✗ 41% CR ✗ 35% severe infections including death ✗ Grade 3 ICANS neurotoxicity reported	✓ **0% neurotoxicity (0/16) in relapsed/refractory AL amyloidosis patients** • **One-time dosing with durable responses** • **Ongoing NEXCART-1 relapsed/refractory AL amyloidosis clinical trial with clinical data presented at ASH 2024**
• Repeat/ongoing dosing with need for healthcare provider to administer	

Advantages of NXC-201 CAR-T in AL Amyloidosis

Source: Feasibility of a Novel Academic Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis, 65th ASH Annual Meeting and Exposition, San Diego, CA. October 2023. R. Chakraborty, et al. Safety and efficacy of teclistamab in systemic immunoglobulin light chain amyloidosis. Blood Cancer Journal. October 2023. N. Forgeard, et al. Teclistamab in relapsed or refractory AL amyloidosis, a multinational retrospective case series. Blood. February 2024. One NXC-201 relapsed/refractory AL amyloidosis patient died of COVID-19

NXC-201 Clinical Development Plan Through FDA BLA Submissions

RELAPSED/REFRACTORY AL AMYLOIDOSIS CLINICAL TRIAL TO ENROLL 40 PATIENTS PRIOR TO FDA BLA SUBMISSION

Relapsed/Refractory AL Amyloidosis NXC-201	Phase 1b/2 NXC-201 Ongoing: NEXICART-1 (Israel) (NCT04720313) NEXICART-2 (US) (NCT06097832)	Expected enrollment duration 18-24 months	40 Patients Single arm, open label	→ Submit to FDA (BLA)	✓ NEXICART-1: 16 patients dosed NEXICART-2: 4 patients dosed at MSK
Select Immune-Mediated Disease Indications NXC-201	U.S. IND Approved		planned single-arm, open-label trials	→ Submit to FDA (BLA)	Site Activation

Note: 63 Relapsed/Refractory multiple myeloma patients have been dosed with NXC-201 in the ex-US NEXICART-1 clinical trial. Immix Biopharma is not actively pursuing US commercial approval in Relapsed/Refractory multiple myeloma at this time.

FDA approval precedents include: Abecma/BMS (single arm study 100 patients in efficacy results population, FDA approved 2021); Carvykti/J&J (single arm study 97 patients in efficacy results population, FDA approved 2022); Elrexfio/Pfizer (single arm study 97 patients in efficacy results population, FDA approved 2023)

NEXICART-1: Durable Responses in NXC-201 AL Amyloidosis Clinical Trial

SWIMMER PLOT ORDER MATCHED TO ASH 2024 PRESENTATION

- Complete hematologic response (CR) of 75% (12/16), a precedent approval endpoint based on the only commercial treatment for AL amyloidosis

- Ongoing NEXICART-2 US trial targeting patients reflective of durable responders



sCR: strict complete response, CR: complete response

Note: E Lebel et al. Efficacy and Safety of Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) for the Treatment of Relapsed and Refractory AL Amyloidosis. Presentation. ASH 2024. Patient 9 death due to depression.

World-Class Team

Management

Ilya Rachman, MD, PhD
Chief Executive Officer

Gabriel Morris, BA
Chief Financial Officer

Graham Ross, MBChB, FFPM
Chief Medical Officer

David Marks, MBBS, PhD
Chief Medical Officer,
Cell Therapy

Gerhard Bauer
Head of Cell Therapy
Manufacturing

Board of Directors

Helen Adams, CPA
Former Prometheus
Biosciences Board Member

Magda Marquet, PhD
ALMA Life Sciences

Jane Buchan, PhD
CEO, Martlet Asset
Management

Yekaterina Chudnovsky, JD
GI Research Foundation

Jason Hsu, PhD
Founder & Chairman,
Rayliant Global Advisors

Carey Ng, PhD
Mesa Verde Venture Partners

Business Advisors

Mary Sue Coleman, PhD
Former Johnson & Johnson
Board Member

Jeffrey H. Cooper, MBA
Former BioMarin
Chief Financial Officer

Edward J. Borkowski, CPA, MBA
Former Mylan
Chief Financial Officer

Henry A. McKinnell, PhD
Former Pfizer
Chief Executive Officer

Scientific Advisory Board

Heather Landau, MD
Director, Amyloidosis Program

Suzanne Lentzsch, MD, PhD
Director, Multiple Myeloma
and Amyloidosis

Michaela Liedtke, MD
Co-Director, Stanford
Amyloid Center

Vaishali Sanchorawala, MD
Director, Amyloidosis Center

Marko Radic, PhD
Autoimmune CAR-T Pioneer

Gary Schiller, MD
UCLA Professor of Oncology

Principal Investigator for NEXICART-2: Heather Landau, MD

- **Director of the Amyloidosis Program and a Bone Marrow Transplant Specialist & Cellular Therapist at Memorial Sloan-Kettering Cancer Center in New York.**
- Authored more than 100 peer-reviewed publications.
- Dr. Landau received her medical degree from SUNY Upstate Medical University, completed her Internal Medicine residency at University of Colorado and her Hematology & Oncology fellowship at Memorial Sloan Kettering Cancer Center.

NXC-201 CAR-T cells penetrate tissues and repeat kill disease-causing cells in AL Amyloidosis

AL Amyloidosis pathologic light chains emerge from deep in the bone marrow where they are produced by pathologic antibody factory plasma cells

Traditional antibody-based therapies primarily address passively accessible target cells

NXC-201 is the only AL amyloidosis therapy in clinical development that actively penetrates deep into the bone marrow



Immunoperoxidase with hematoxylin counterstain, ×100



Periodic acid–Schiff, ×100

Antibody-based therapeutics have difficulty penetrating deep into organs where disease causing plasma cells reside

Inserm

"Plasma cells (PC) were detected in the [organs] of patients … up to 6 months after rituximab treatment, and the PC population displayed a long-lived program"

doi:10.1172/JCI65689

Source: N Swan et al. Bone Marrow Core Biopsy Specimens in AL (Primary) Amyloidosis. Hematopathology. Am J Clin Pathol 2003. DOI: 10.1309/PFUGHBX0TY20E08U.. Mahévas M, et al. B cell depletion in immune thrombocytopenia reveals splenic long-lived plasma cells. J Clin Invest. 2013 Jan;123(1):432-42. doi: 10.1172/JCI65689. Epub 2012 Dec 17. PMID: 23241960; PMCID: PMC3533302.

Pathologic Light Chains in AL Amyloidosis are an Antibody Building Block That Are Overproduced by Plasma Cells

A LIGHT CHAIN IS A PORTION OF AN ANTIBODY

Light chain portion of antibody

Heavy chain portion of antibody



Normal antibody produced by plasma cell

IN AL, PLASMA CELLS PRODUCE TOO MANY LIGHT CHAINS



Diseased light chains in AL Amyloidosis: excessive production by plasma cells

AL amyloid antibody deposits



Infiltrates and damages heart

This Is Pre-Existing Heart Failure in AL Amyloidosis

PRE-EXISTING HEART FAILURE CAUSES PHYSICALLY IRREVERSIBLE DISTORTION OF HEART STRUCTURE, SHAPE AND SIZE

Pre-existing heart failure

Preserved heart function



Robust Global Sales of CAR-T Continue





Note: Full year 2024 sales estimated based on annualized quarterly 2024 actual sales
Source: Company reports

Amyloid deposits in AL Amyloidosis are cleared naturally after treatment

BEFORE TREATMENT

Pre-treatment imaging shows dense amyloid deposits in liver, bone marrow, and other organs in AL patient



Cytotoxic treatments (vincristine, adriamycin, and dexamethasone)

6-MONTHS AFTER TREATMENT



Post-treatment imaging shows clearance of amyloid in organs throughout the body

Source: Adapted from Lovat LB, Persey MR, Madhoo S, Pepys MB, Hawkins PN. The liver in systemic amyloidosis: insights from 123I serum amyloid P component scintigraphy in 484 patients. Gut. 1998 May;42(5):727-34. doi: 10.1136/gut.42.5.727. PMID: 9659172; PMCID: PMC1727098.

Complete Hematologic Response is correlated with longer survival

COMPLETE HEMATOLOGIC RESPONSE WAS PRIMARY ENDPOINT IN 2021 DARATUMUMAB APPROVAL STUDY AND ONGOING NEXICART-2 TRIAL

Complete Hematologic Response (CR) associated with improved survival in AL



2x survival at 48 months for CR vs PR

- Complete Hematologic response patients have 85% survival at 48 months
- Partial hematologic response patients have 40% survival at 48 months

Source: Adapted from Palladini G, Dispenzieri A, Gertz MA, Kumar S, Wechalekar A, Hawkins PN, Schönland S, Hegenbart U, Comenzo R, Kastritis E, Dimopoulos MA, Jaccard A, Klersy C, Merlini G. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol. 2012 Dec 20;30(36):4541-9. doi: 10.1200/JCO.2011.37.7614. Epub 2012 Oct 22. PMID: 23091105.

MRD- is Correlated with Improved PFS in AL Amyloidosis

MRD negativity is associated with improved Progression Free Survival in AL



2x PFS at 36 months for MRD- vs MRD+
(patients with CR or VGPR)

- MRD negative patients have 88% 36-month PFS
- MRD positive patients have 46% 36-month PFS

Note: Adapted from Muchtar E, Dispenzieri A, Jevremovic D, Dingli D, Buadi FK, Lacy MQ, Gonsalves W, Warsame R, Kourelis TV, Hayman SR, Kapoor P, Leung N, Russell S, Lust JA, Lin Y, Go RS, Zeldenrust S, Kyle RA, Rajkumar SV, Kumar SK, Gertz MA. Survival impact of achieving minimal residual negativity by multi-parametric flow cytometry in AL amyloidosis. Amyloid. 2020 Mar;27(1):13-16. doi: 10.1080/13506129.2019.1666709. Epub 2019 Sep 23. PMID: 31544536; PMCID: PMC7372715.

N-GENIUS Sterically-Optimized CARTs Drive Immix's Immune-Mediated Disease Leadership

N-GENIUS Platform

Through partnership Hadassah Medical Organization, Jerusalem and Bar-Ilan University, Immix is a pioneer in sterically-optimized CAR-T construct development, driving our next-generation industry-leading CAR-Ts in select immune-mediated diseases.

N-GENIUS developed sterically-optimized CAR-Ts allow for a differentiated safety and efficacy profile through modification of key regions of the CAR-T construct, driving a "digital" intracellular signal and overcoming limitations of current clinical stage and commercial CAR-Ts.

Portfolio of US patents, pending applications, and exclusive patent licenses, which cover our core technology platforms and product

Hadassah University Hospital

Bar-Ilan University
אוניברסיטת בר־אילן

N-GENIUS Platform has produced sterically-optimized BCMA CAR-T NXC-201 with COBRA binder and EXPAND technology

ALL BCMA CAR-TS ARE NOT CREATED EQUAL

N-GENIUS PLATFORM

3 Key Elements

Purpose-Built Cell Therapy Evidence Capture Engine + Relational Database

Relating ImmixBio internal data to external to accelerate therapy design, manufacture, and preclinical

Proprietary EXPAND technology

Applied to multiple cell therapy indications, already utilized to create NXC-201, to potentially increase efficacy and tolerability

Atomized, Novel Binding Scaffold Generation Engine

Allows us to make the correct binding for every molecule

Produced NXC-201



Source:. Aherie, N., et al Haematologica. 2022

NXC-201 MoA: Sterically-Optimized BCMA-targeted CAR-T

NXC-201: STERICALLY-OPTIMIZED BCMA CAR-T GENERATED BY THE N-GENIUS PLATFORM

NXC-201



NXC-201 is a next-generation chimeric antigen receptor (CAR) T-cell (CAR-T) produced by our N-GENIUS platform targeting B-cell maturation antigen (BCMA)

- High Overall Response Rates in AL Amyloidosis and Multiple Myeloma
- First Outpatient CAR-T: Short CRS duration (median 1 days) starting on day 1

NXC-201 — Key Characteristics

High Transduction Efficiency
(Ensuring efficient manufacturing)

*Carvykti data presented at ASH 2019; Abecma data presented at ASH 2017. CART-ddBCMA source Arcellx. Analysis based on cross-trial comparisons of publicly available data reported in ASH 2017 and 2019 and not a head-to-head clinical trial



Low Tonic Signaling
(Lower off-target toxicity may lead to lower toxicity)

NXC-201 was co-cultured with the indicated target T cells and TNFα (B) and IL-2 (C) concentrations secreted in the culture supernatant were determined by ELISA.

Anti-Exhaustion Capability
(Increased Persistence may lead to efficacy over an extended period of time)

NXC-201 was co-cultured overnight then analyzed by flow cytometry for the expression of 4-1BB



Source: Development and manufacturing of novel locally produced anti-BCMA CART cells for the treatment of relapsed/refractory multiple myeloma: phase I clinical results. Haematologica. 2022 Oct 6. doi: 10.3324/haematol.2022.281628. Epub ahead of print. PMID: 36200421.

Proprietary EXPAND Technology and COBRA Binding Domain Are Differentiated Innovations

N-GENIUS TECHNOLOGY PLATFORM: STERICALLY-OPTIMIZED BCMA CAR-T NXC-201



Note: Graphic representation. COBRA = Codon Optimized Binder for Receptor Antigens – Proprietary Binding Domain

NXC-201 Best-in-Class AL Amyloidosis Clinical Results

Relapsed/Refractory Light chain (AL) Amyloidosis

	NXC-201 Monotherapy	Darzalex Combination (with cyclophosphamide, bortezomib, and/or dexamethasone)	CAEL-101	**Birtamimab Combined with SOC CyBorD**
Dosing frequency	1X	Weekly	Weekly	Weekly
Patient #s: n=	16	9	10 (renal), 24 (cardiac)	14 (cardiac), 15 (renal)
Hematologic Overall Response Rate	94%	22%	-	-
Hematologic Complete Response Rate	75%	0%	-	-
Hematologic CR + VGPR	88%	22%	-	-
Cardiac response – (NT-proBNP median reduction)	78%		39%	35%
Renal response (%)	33%		20%	60%
Median prior lines of therapy	4	1	2	2
% pretreated with CD38-targeted treatment (Darzalex/other)	100%	100%	?	0%

Birtamimab Source from JCO (Birtamimab development paused + restarted). CAEL-101 source: Edwards CV, et al. Phase 1a/b study of monoclonal antibody CAEL-101 (11-1F4) in patients with AL amyloidosis. Blood. 2021 Dec 23;138(25):2632-2641. doi: 10.1182/blood.2020009039. PMID: 34521113; PMCID: PMC8703360. Darzalex source from Blood. Point-of-care CART manufacture and delivery: Poster. Poster Presentation, ESBMT 2023. Poster ASGCT 2023. Figures reflect cross-trial comparison and not results from a head-to head study. Differences exist between trial designs and subject characteristics, and caution should be exercised when comparing data across studies.Poster: IMS 2023. Poster: ASH 2023. Darzalex and Investigator's Choice : Theodorakakou, et al, Blood 2022. Astra Zeneca: Blood 2021 12 NXC-201 patients at ASGCT 2024 with no prior exposure to BCMA targeted bispecifics

Differentiated NXC-201 safety profile validated in historical Multiple Myeloma data

NXC-201 tolerability data in Relapsed/Refractory Multiple Myeloma

Cytokine release syndrome

	Cohort 1 (N=6)	Cohort 2 (N=7)	Cohort 3 (N=50)	Overall (n=63)
Dose	**150M**	**450M**	**800M**	
CRS (n [%])				
Yes	5 (83%)	6 (86%)	48 (96%)	59 (94%)
No	1 (17%)	1 (14%)	2 (4%)	4 (6%)
CRS Start Day				
Median	6	0	0	
Min, Max	0, 21	0, 1	0, 4	
CRS Duration				
Median	3	2	1	
Min, Max	0, 5	1, 3	1, 7	
CRS Grade (n [%])				
No CRS	1 (17%)	1 (14%)	2 (4%)	4 (6%)
1	4 (67%)	2 (29%)	17 (34%)	23 (37%)
2	1 (17%)	4 (57%)	24 (48%)	29 (46%)
3	0 (0%)	0 (0%)	7 (14%)	7 (11%)
4	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Tocilizumab (n [%])				
Yes	2 (33%)	4 (57%)	40 (80%)	46 (73%)
No	4 (67%)	3 (43%)	10 (20%)	17 (27%)
Steroids (n [%])				
Yes	0 (0%)	0 (0%)	8 (16%)	8 (13%)
No	6 (100%)	7 (100%)	42 (84%)	55 (87%)
Vasopressors (n [%])				
Yes	0 (0%)	0 (0%)	7 (14%)	7 (11%)
No	6 (100%)	7 (100%)	43 (86%)	56 (89%)

ICANS neurotoxicity

	Cohort 1 (N=6)	Cohort 2 (N=7)	Cohort 3 (N=50)	Overall (n=63)
Dose	**150M**	**450M**	**800M**	
ICANS (n [%])				
Yes	0 (0%)	0 (0%)	2 (4%)	2 (3%)
No	6 (100%)	7 (100%)	48 (96%)	61 (97%)
ICANS Grade (n [%])				
1-2	0 (0%)	0 (0%)	2 (4%)	2 (3%)
3-4	0 (0%)	0 (0%)	0 (0%)	0 (0%)

NXC-201 at 150M and 450M CAR+T cell dose (US AL Amyloidosis trial dosing):

- 0% Grade 3+ CRS
- 0% ICANS of any grade

Source: Kfir-Erenfeld S, Asherie N, Lebel E, Vainstein V, Assayag M, Dubnikov Sharon T, Grisariu S, Avni B, Elias S, Alexander-Shani R, Bessig N, Shehadeh A, Ishtay A, Zelmanovich V, Zimran E, Pick M, Roziner I, Kenett RS, Cohen Y, Avivi I, Cohen CJ, Gatt ME, Stepensky P. Clinical evaluation and determinants of response to HBI0101 (BCMA CART) therapy in relapsed/refractory multiple myeloma. Blood Adv. 2024 Aug 13;8(15):4077-4088. doi: 10.1182/bloodadvances.2024012967. PMID: 38768428. Asherie N, Kfir-Erenfeld S, Avni B, Assayag M, Dubnikov T, Zalcman N, Lebel E, Zimran E, Shaulov A, Pick M, Cohen Y, Avivi I, Cohen C, Gatt ME, Grisariu S, Stepensky P. Development and manufacture of novel locally produced anti-BCMA CAR T cells for the treatment of relapsed/refractory multiple myeloma: results from a phase I clinical trial. Haematologica. 2023 Jul 1;108(7):1827-1839. doi: 10.3324/haematol.2022.281628. PMID: 36200421; PMCID: PMC10316256.

Relapsed/Refractory Multiple Myeloma: Key Inclusion Criteria

	NXC-201 (NEXICART-1 NCT04720313)	Abecma (pivotal NCT03361748)	Carvykti (pivotal NCT03548207)	CART-ddBCMA (pivotal NCT05396885)
Prior lines of therapy	≥3 different prior lines of therapy including proteasome inhibitor, immunomodulatory therapy and ≥1 antibody therapy, refractory/ responsive to the last line of therapy	≥3 different prior lines of therapy including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 antibody, refractory to the last treatment regimen	≥3 different prior lines of therapy including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 antibody, refractory to the last treatment regimen, refractory or non-responsive to their most recent line of therapy	≥3 different prior lines of therapy including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 antibody, refractory to the last treatment regimen
Toxicity recovery	Recovery to ≤Grade 2 or baseline of any non-hematologic toxicities due to prior treatments, excluding alopecia and Grade 3 neuropathy	Recovery to Grade 1 or baseline of any non-hematologic toxicities due to prior treatments	-	Resolution of adverse events (AEs) from any prior systemic anticancer therapy, radiotherapy, or surgery to Grade 1 or baseline
ECOG	0-2	0-1	0-1	0-1
Measurable disease	• Serum M-protein greater or equal to 0.5 g/dL • Urine M-protein greater or equal to 200 mg/24 h • Serum free light chain (FLC) assay: involved FLC level greater or equal to 5 mg/dL (50 mg/L) provided serum FLC ratio is abnormal	• Serum M-protein greater or equal to 1.0 g/dL • Urine M-protein greater or equal to 200 mg/24 h • Serum free light chain (FLC) assay: involved FLC level greater or equal to 10 mg/dL (100 mg/L) provided serum FLC ratio is abnormal	• Serum monoclonal paraprotein (M-protein) level more than or equal to (>=) 1.0 gram per deciliter(g/dL) • Urine M-protein level >=200 milligram per 24 hours (mg/24hr) • Light chain multiple myeloma without measurable disease in the serum or the urine: Serum immunoglobulin free light chain 10 mg/dL and abnormal serum immunoglobulin kappa lambda free light chain ratio	• Serum M-protein ≥1.0 g/dL • Urine M-protein ≥200 mg/24 hours • Involved serum free light chain ≥10 mg/dL with abnormal κ/λ ratio (i.e., >4:1 or <1:2)

Source: Clinicaltrials.gov; Asherie N, et al. Haematologica. 2023

Relapsed/Refractory Multiple Myeloma: Key Exclusion Criteria

	NXC-201 (NEXICART-1 NCT04720313)	Abecma (pivotal NCT03361748)	Carvykti (pivotal NCT03548207)	CART-ddBCMA (pivotal NCT05396885)
Prior BCMA therapy	No exclusion	BCMA targeted therapy	Have received any therapy that is targeted to B-cell maturation antigen (BCMA)	Prior B-cell maturation antigen (BCMA) directed therapy
Prior cell therapy	Investigational cellular therapies within 8 weeks prior to the start of lymphodepletion	Investigational cellular therapy for cancer	Have received prior treatment with chimeric antigen receptor T (CAR-T) therapy directed at any target	Prior treatment with any gene therapy or gene-modified cellular immune-therapy

Source: Clinicaltrials.gov; Asherie N, et al. Haematologica. 2023

What is autologous chimeric antigen receptor (CAR)-T cell therapy?

NXC-201 IS A NEXT-GENERATION BCMA TARGETED AUTOLOGOUS CAR-T CELL THERAPY



Patient Specific

Personalized treatment using patient's own T cells

Genetic Modification

Genetically engineered CARs (chimeric antigen receptors) on T cell surface

Targeted Therapy

Target cells that express antigens recognized by CARs

Source: Adapted from Texas Oncology. CAR-T Therapy. https://www.texasoncology.com/services-and-treatments/treatments/car-t-therapy

N-GENIUS Platform Process

1

Problem Identification

CAR-T Toxicity Main Block to Widespread Use: Neurotoxicity

2

Research Group Formation

Reduce CAR-T Toxicity while Improving Efficacy

3

Platform Foundation

N-GENIUS Platform with EXPAND Technology aims to achieve research group goal

4

Candidate Creation

Entire CAR-T construct optimized with N-GENIUS Platform and EXPAND Technology In Selected Indications

5

Final Candidate Selection

4 promising candidates selected among a larger number of options



6

Human Peripheral blood mononuclear cells (PBMC) were transduced with the CAR candidates



7

CAR-T Transgene expression was assessed by flow cytometry



8

Co-culture of CAR-T cells and target cells with target antigens and in vitro analysis of cytokine release



9

Evaluation CAR-T activity in vivo (tumor growth, cytokine release, safety evaluation)



10

NXC-201

Source:: Harush O, et al. Haematologica. 2022;

Clinical Stage CAR-T for AL Amyloidosis and Select Immune-Mediated Diseases

February 2025

IMMiX BIOPHARMA